BRIEF — Merck’S Remigromig, A Tri — Specific Agonist Of The Wingless — Related Integration Site Pathway, Met Primary Endpoint In The Pivotal Phase 2B/3 Brunello Study Of Adults With Diabetic Macular Edema

Sept 24 (Reuters) — Merck & Co Inc: Merck’s Remigromig, A Tri-specific Agonist Of The Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint In The Pivotal Phase 2b/3 Brunello Study Of Adults With Diabetic Macular Edema Merck & Co - Remigromig Demonstrates Non-inferiority To Ranibizumab For Bcva At Week 52 Merck & Co - Both Remigromig Doses Show Non-inferiority To Ranibizumab At 52 Weeks Merck & Co - Higher Rates Of Pdr, Vitreous Hemorrhage, And Discontinuations With Remigromig Merck & Co Inc: Both Doses Of Remigromig Were Generally Well Tolerated Source text:... Further company coverage: MRK.N (Reuters.Briefs@thomsonreuters.com;)